Evidence map›Paper›PMID 39470968›Full record

ArticleFolia microbiologica2025

Targeting virulence of resistant Escherichia coli by the FDA-approved drugs sitagliptin and nitazoxanide as an alternative antimicrobial approach.

Sara M Eltabey, Ali H Ibrahim, Mahmoud M Zaky, Adel Ehab Ibrahim, Yahya Bin Abdullah Alrashdi, Sami El Deeb, Moustafa M Saleh

Abstract read
PubMed Publisher
In one paragraph

Article in Folia microbiologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Molecular Characterization of vanA and blaMolecular biology reports · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sara M EltabeyMicrobiology Program, Botany Department, Faculty of Science, Port Said University, Port Said, Egypt.
Ali H IbrahimBotany Department, Faculty of Science, Port Said University, Port Said, Egypt.
Mahmoud M ZakyBotany Department, Faculty of Science, Port Said University, Port Said, Egypt.
Adel Ehab IbrahimNatural and Medical Sciences Research Center, University of Nizwa, Birkat Al Mauz, P.O. Box 33, Nizwa, 616, Oman. adel@unizwa.edu.om.ORCID http://orcid.org/0000-0001-7421-1220
Yahya Bin Abdullah AlrashdiCollege of Pharmacy and Nursing, University of Nizwa, Birkat Al Mauz, Nizwa, 616, Oman.
Sami El DeebInstitute of Medicinal and Pharmaceutical Chemistry, Technische Universitaet Braunschweig, Brunswick, Germany. s.eldeeb@tu-bs.de.
Moustafa M SalehMicrobiology and Immunology Department, Faculty of Pharmacy, Port Said University, Port Said, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The spread of multidrug-resistant Escherichia coli in healthcare facilities is a global challenge. Hospital-acquired infections produced by Escherichia coli include gastrointestinal, blood-borne, urinary tract, surgical sites, and neonatal infections. Therefore, novel approaches are needed to deal with this pathogen and its rising resistance. The concept of attenuating virulence factors is an alternative strategy that might lead to low levels of resistance and combat this pathogen. A sub-inhibitory concentration (¼ MIC) of sitagliptin and nitazoxanide was used for phenotypic assessments of Escherichia coli virulence factors such as biofilm production, swimming motility, serum resistance, and protease production. Moreover, qRT-PCR was used to determine the impact of sub-MIC of the tested drugs on the relative expression levels of papC, fimH, fliC, kpsMTII, ompT_m, and stcE genes encoding virulence factors in Escherichia coli. Also, an in vivo model was conducted as a confirmatory test. Phenotypically, our findings demonstrated that the tested strains showed a significant decrease in all the tested virulence factors. Moreover, the genotypic results showed a significant downregulation in the relative expression levels of all the tested genes. Besides, the examined drugs were found to be effective in protecting mice against Escherichia coli pathogenesis. Sitagliptin and nitazoxanide exhibited strong anti-virulence activities against Escherichia coli. In addition, it is recommended that they might function as adjuvant in the management of Escherichia coli infections with either conventional antimicrobial agents or alone as alternative treatment measures.

Indexed as

Anti-Bacterial AgentsEscherichia coliEscherichia coli InfectionsSitagliptin PhosphateThiazolesAnimalsBiofilmsDrug Resistance, Multiple, BacterialEscherichia coli ProteinsFemaleHumansMiceMicrobial Sensitivity TestsNitro CompoundsVirulenceVirulence FactorsAnti-Bacterial AgentsEscherichia coli ProteinsnitazoxanideNitro CompoundsSitagliptin PhosphateThiazolesVirulence FactorsAntibiotic resistanceEscherichia coliNitazoxanideSitagliptinVirulence inhibitors

Identifiers

PMID39470968

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.